Extensive evidence has shown that Nur77 is a critical suppressor of lipid metabolism in breast cancer, and Nur77 deficiency often indicates a worse prognosis.[6] However, the activated Nur77‐PPARγ signaling pathway plays an antagonistic role in the Nur77‐mediated process, and identifying direct inhibitors of the Nur77‐PPARγ interaction without a cocrystal structure is challenging. Here, PPARG is linked to breast cancer.